Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 413076, 21 pages
http://dx.doi.org/10.1155/2015/413076
Review Article

Paclitaxel and Its Evolving Role in the Management of Ovarian Cancer

1Department of Immunology, Monash University, Level 6, The Alfred, Commercial Road, Melbourne, VIC 3181, Australia
2Gynaeoncology Unit, Royal Women’s Hospital, 20 Flemington Road, Parkville, Melbourne, VIC 3052, Australia
3Department of Obstetrics and Gynaecology, University of Melbourne, Melbourne, VIC 3052, Australia

Received 20 February 2015; Accepted 7 April 2015

Academic Editor: Rohit S. Mulik

Copyright © 2015 Nirmala Chandralega Kampan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Citations to this Article [72 citations]

The following is the list of published articles that have cited the current article.

  • Yingyi Liu, Sujie Gao, Xuebo Chen, Meihan Liu, Cuiying Mao, and Xuedong Fang, “Overexpression of miR-203 sensitizes paclitaxel (Taxol)-resistant colorectal cancer cells through targeting the salt-inducible kinase 2 (SIK2),” Tumor Biology, 2016. View at Publisher · View at Google Scholar
  • Pritam Thapa, Mengjie Li, Moses Bio, Pallavi Rajaputra, Gregory Nkepang, Yajing Sun, Sukyung Woo, and Youngjae You, “Far-Red Light-Activatable Prodrug of Paclitaxel for the Combined Effects of Photodynamic Therapy and Site-Specific Paclitaxel Chemotherapy,” Journal of Medicinal Chemistry, 2016. View at Publisher · View at Google Scholar
  • Harmeet Kaur, Virender Kumar, Jasbir Singh, Sapna D. Desai, and Pooja Rathi, “Heterocyclic drug-polymer conjugates for cancer targeted drug delivery,” Mini-Reviews in Medicinal Chemistry, vol. 16, no. 17, pp. 1355–1377, 2016. View at Publisher · View at Google Scholar
  • David Howard, Jetzabel Garcia-Parra, Gareth D. Healey, Cynthia Amakiri, Lavinia Margarit, Lewis W. Francis, Deyarina Gonzalez, and R. Steven Conlan, “Antibody–drug conjugates and other nanomedicines: the frontier of gynaecological cancer treatment,” Interface Focus, vol. 6, no. 6, pp. 20160054, 2016. View at Publisher · View at Google Scholar
  • Manish Kumar Pal, Shyama. Pyari Jaiswar, Ajeet Kumar Srivastav, Shruti Goyal, Ashish Dwivedi, Ankit Verma, Jyoti Singh, Anumesh Kumar Pathak, Pushpa.Lata Sankhwar, and Ratan.Singh Ray, “Synergistic effect of piperine and paclitaxel on cell fate via cyt-c,bax/bcl-2-caspase-3 pathway in ovarian adenocarcinomas SKOV-3 cells,” European Journal of Pharmacology, 2016. View at Publisher · View at Google Scholar
  • Shuai Hao, Bo Gao, Wu-Guo Tian, Xiao-Hua Zhang, Yan Jiang, Shu Zhang, Ling-Ji Guo, and Dong-Lin Luo, “A network meta-analysis for toxicity of eight chemotherapy regimens in the treatment of metastatic/advanced breast cancer,” Oncotarget, vol. 7, no. 51, pp. 84533–84543, 2016. View at Publisher · View at Google Scholar
  • Vijayalakshmi N. Ayyagari, Paula L. Diaz-Sylvester, Tsung-han Jeff Hsieh, and Laurent Brard, “Evaluation of the cytotoxicity of the Bithionol-paclitaxel combination in a panel of human ovarian cancer cell lines,” Plos One, vol. 12, no. 9, pp. e0185111, 2017. View at Publisher · View at Google Scholar
  • Fang Guan, Lan Xie, Shoujun Yuan, Lili Wang, Rui Ding, Qi Zhang, Wei Chen, Feifei Li, Long Long, Wei Li, Linna Li, and Dexuan Yang, “WX-132-18B, a novel microtubule inhibitor, exhibits promising anti-tumor effects.,” Oncotarget, vol. 8, no. 42, pp. 71782–71796, 2017. View at Publisher · View at Google Scholar
  • Bo Eun Lee, Bo Young Choi, Dae Kee Hong, Jin Hee Kim, Song Hee Lee, A Ra Kho, Haesung Kim, Hui Chul Choi, and Sang Won Suh, “The cancer chemotherapeutic agent paclitaxel (Taxol) reduces hippocampal neurogenesis via down-regulation of vesicular zinc,” Scientific Reports, vol. 7, no. 1, 2017. View at Publisher · View at Google Scholar
  • Nusrat Chowdhury, Imran Vhora, Ketan Patel, Ravi Doddapaneni, Arindam Mondal, and Mandip Singh, “Liposomes co-Loaded with 6-Phosphofructo-2-Kinase/Fructose-2, 6-Biphosphatase 3 (PFKFB3) shRNA Plasmid and Docetaxel for the Treatment of non-small Cell Lung Cancer,” Pharmaceutical Research, 2017. View at Publisher · View at Google Scholar
  • Shareni Jeyamogan, Naveed Ahmed Khan, and Ruqaiyyah Siddiqui, “Animals living in polluted environments are a potential source of anti-tumor molecule(s),” Cancer Chemotherapy and Pharmacology, 2017. View at Publisher · View at Google Scholar
  • Ezequiel Bernabeu, Maximiliano Cagel, Eduardo Lagomarsino, Marcela Moretton, and Diego A. Chiappetta, “Paclitaxel: What has been done and the challenges remain ahead,” International Journal of Pharmaceutics, 2017. View at Publisher · View at Google Scholar
  • Michael Jelinek, Adela Kabelova, Jan Sramek, Joshua Seitz, Iwao Ojima, and Jan Kovar, “Differing mechanisms of death induction by fluorinated taxane SB-T-12854 in breast cancer cells,” Anticancer Research, vol. 37, no. 4, pp. 1581–1590, 2017. View at Publisher · View at Google Scholar
  • Hwa Jun Cha, Jung Hye Choi, In Chul Park, Chun Ho Kim, Sung Kwan An, Tae Jin Kim, and Jae Ho Lee, “Selective FGFR inhibitor BGJ398 inhibits phosphorylation of AKT and STAT3 and induces cytotoxicity in sphere-cultured ovarian cancer cells,” International Journal of Oncology, vol. 50, no. 4, pp. 1279–1288, 2017. View at Publisher · View at Google Scholar
  • Zeina Habli, Georgio Toumieh, Maamoun Fatfat, Omar Rahal, and Hala Gali-Muhtasib, “Emerging Cytotoxic Alkaloids in the Battle against Cancer: Overview of Molecular Mechanisms,” Molecules, vol. 22, no. 2, pp. 250, 2017. View at Publisher · View at Google Scholar
  • Satabdi Datta, Diptiman Choudhury, Amlan Das, Dipanwita Das Mukherjee, Nabanita Das, Sib Sankar Roy, and Gopal Chakrabarti, “Paclitaxel resistance development is associated with biphasic changes in reactive oxygen species, mitochondrial membrane potential and autophagy with elevated energy production capacity in lung cancer cells: A chronological study,” Tumor Biology, vol. 39, no. 2, pp. 101042831769431, 2017. View at Publisher · View at Google Scholar
  • Margo Steuperaert, Giuseppe Falvo D’Urso Labate, Charlotte Debbaut, Olivier De Wever, Christian Vanhove, Wim Ceelen, and Patrick Segers, “Mathematical modeling of intraperitoneal drug delivery: simulation of drug distribution in a single tumor nodule,” Drug Delivery, vol. 24, no. 1, pp. 491–501, 2017. View at Publisher · View at Google Scholar
  • Lianzhi Cui, Yawei Zhao, Yue Pan, Xiao Zheng, Dan Shao, Kan He, Kun Li, Li Chen, and Yong Jia, “Chemotherapy induces ovarian cancer cell repopulation through the caspase 3-mediated arachidonic acid metabolic pathway,” OncoTargets and Therapy, vol. 10, pp. 5817–5826, 2017. View at Publisher · View at Google Scholar
  • Mingzi Zhang, Zhongkai Tian, and Yehong Sun, “Successful treatment of ovarian cancer with apatinib combined with chemotherapy,” Medicine, vol. 96, no. 45, pp. e8570, 2017. View at Publisher · View at Google Scholar
  • Chang-Ping Qu, Gui-Xia Sun, Shao-Qin Yang, Jun Tian, Jin-Ge Si, and Yi-Feng Wang, “Toxicities of different first-line chemotherapy regimens in the treatment of advanced ovarian cancer,” Medicine, vol. 96, no. 2, pp. e5797, 2017. View at Publisher · View at Google Scholar
  • V. G. Bespalov, E. A. Vyshinskaya, I. N. Vasil’eva, A. L. Semenov, M. A. Maidin, N. V. Barakova, and A. N. Stukov, “Comparative Study of Antitumor Efficiency of Intraperitoneal and Intravenous Cytostatics in Experimental Rats with Disseminated Ovarian Cancer,” Bulletin of Experimental Biology and Medicine, vol. 162, no. 3, pp. 383–386, 2017. View at Publisher · View at Google Scholar
  • Xi-Ping Jiang, Xiao-Hui Rui, Cai-Xia Guo, Ya-Qing Huang, Qin Li, and Yun Xu, “A network meta-analysis of eight chemotherapy regimens for treatment of advanced ovarian cancer,” Oncotarget, vol. 8, no. 12, pp. 19125–19136, 2017. View at Publisher · View at Google Scholar
  • Shih-Ting Huang, Yen-Hui Chen, Yi-Ping Wang, Chin-Tarng Lin, Wen-Shan Li, and Han-Chung Wu, “Liposomal paclitaxel induces fewer hematopoietic and cardiovascular complications than bioequivalent doses of Taxol,” International Journal of Oncology, vol. 53, no. 3, pp. 1105–1117, 2018. View at Publisher · View at Google Scholar
  • Iva Guberović, Marko Marjanović, Marija Mioč, Katja Ester, Irena Martin-Kleiner, Tatjana Šumanovac Ramljak, Kata Mlinarić-Majerski, and Marijeta Kralj, “Crown ethers reverse P-glycoprotein-mediated multidrug resistance in cancer cells,” Scientific Reports, vol. 8, no. 1, 2018. View at Publisher · View at Google Scholar
  • Guanhua Qian, and Tinghe Yu, “Nanosecond Electric Pulses Induce Early and Late Phases of DNA Damage and Cell Death in Cisplatin-Resistant Human Ovarian Cancer Cells,” BioMed Research International, vol. 2018, pp. 1–7, 2018. View at Publisher · View at Google Scholar
  • Amy C. Brown, “Cancer Related to Herbs and Dietary Supplements: Online Table of Case Reports. Part 5 of 5,” Journal of Dietary Supplements, vol. 15, no. 4, pp. 556–581, 2018. View at Publisher · View at Google Scholar
  • Lena Paukov, Ziv Cohen, Irit Shapira, Ohad Bejamini, Abraham Avigdor, Igor Koman, Gabriela Rozic, Merav Leiba, Adrian Duek, and Arnon Nagler, “STK405759 as a combination therapy with bortezomib or dexamethasone, in in vitro and in vivo multiple myeloma models,” Oncotarget, vol. 9, no. 59, pp. 31367–31379, 2018. View at Publisher · View at Google Scholar
  • Bo Young Choi, and Sang Won Suh, “Antimicrotubule Agent-Induced Zinc Neurotoxicity,” Biological and Pharmaceutical Bulletin, vol. 41, no. 7, pp. 1001–1005, 2018. View at Publisher · View at Google Scholar
  • Shivaswamy Santosh, Manasa Deepa Rajagopalan, Bangalore Acharlu Pallavi, Gudepalya Renukaiah Rudramurthy, Valluru Rajashekar, Katta Annaiah Sridhar, and Mallappa Kumara Swamy, “Cancer Therapies: Current Scenario, Management, and Safety Aspects,” Anticancer Plants: Clinical Trials and Nanotechnology, pp. 1–25, 2018. View at Publisher · View at Google Scholar
  • Arun T. Patil, Amol A. Tatode, and Milind J. Umekar, “Application of response surface methodology in optimization of paclitaxel liposomes prepared by thin film hydration technique,” International Journal of Applied Pharmaceutics, vol. 10, no. 2, pp. 62–69, 2018. View at Publisher · View at Google Scholar
  • Belinda van Zyl, Denise Tang, and Nikola A Bowden, “Biomarkers of platinum resistance in ovarian cancer: what can we use to improve treatment,” Endocrine-Related Cancer, vol. 25, no. 5, pp. R303–R318, 2018. View at Publisher · View at Google Scholar
  • Mona Alharbi, Omar Elfeky, Gregory E. Rice, Felipe Zuñiga, Dominic Guanzon, Andrew Lai, Lewis Perrin, John Hooper, and Carlos Salomon, “The potential role of miRNAs and exosomes in chemotherapy in ovarian cancer,” Endocrine-Related Cancer, vol. 25, no. 12, pp. R663–R685, 2018. View at Publisher · View at Google Scholar
  • Qing-Nan Tang, Jin-Jie Yan, Zhen-Chong Yang, Ling Guo, Xue-Song Sun, Xiao-Yun Li, Sai-Lan Liu, Yu-Jing Liang, Chao Lin, Lin-Quan Tang, Hai-Qiang Mai, Qiu-Yan Chen, Huan-Xin Lin, Yue-Feng Wen, Shan-Shan Guo, Li-Ting Liu, and Hao-Jun Xie, “Liposomal paclitaxel versus docetaxel in induction chemotherapy using Taxanes, cisplatin and 5-fluorouracil for locally advanced nasopharyngeal carcinoma,” BMC Cancer, vol. 18, no. 1, 2018. View at Publisher · View at Google Scholar
  • Xiaoling Hong, Siying Li, Wanying Li, Min Xie, Zhentong Wei, Haoran Guo, Wei Wei, and Songling Zhang, “Disruption of protein neddylation with MLN4924 attenuates paclitaxel-induced apoptosis and microtubule polymerization in ovarian cancer cells,” Biochemical and Biophysical Research Communications, 2018. View at Publisher · View at Google Scholar
  • Nita Kumar, Rayhaneh Afjei, Tarik F. Massoud, and Ramasamy Paulmurugan, “Comparison of cell-based assays to quantify treatment effects of anticancer drugs identifies a new application for Bodipy-L-cystine to measure apoptosis,” Scientific Reports, vol. 8, no. 1, 2018. View at Publisher · View at Google Scholar
  • Thomas Vangijzegem, Dimitri Stanicki, and Sophie Laurent, “Magnetic iron oxide nanoparticles for drug delivery: applications and characteristics,” Expert Opinion on Drug Delivery, pp. 1–10, 2018. View at Publisher · View at Google Scholar
  • Han-Wei Lin, Tzu-Pin Lu, Wen-Fang Cheng, Chi-Feng Fu, Ming-Cheng Chang, Hsiu-Ping Lin, Ying-Cheng Chiang, and Chi-An Chen, “CDH1, DLEC1 and SFRP5 methylation panel as a prognostic marker for advanced epithelial ovarian cancer,” Epigenomics, vol. 10, no. 11, pp. 1397–1413, 2018. View at Publisher · View at Google Scholar
  • Haonan Li, Runwei Jiao, Jiahui Mu, Shengtao Xu, Xu Li, Xianhua Wang, Zhanlin Li, Jinyi Xu, Huiming Hua, and Dahong Li, “Bioactive Natural Spirolactone-Type 6,7-seco-ent-Kaurane Diterpenoids and Synthetic Derivatives,” Molecules, vol. 23, no. 11, pp. 2914, 2018. View at Publisher · View at Google Scholar
  • Shuning Chen, Yujiao Liu, Shenyin Zhu, Chunyan Chen, Wan Xie, Linlin Xiao, Yi Zhu, Lan Hao, Zhigang Wang, Jiangchuan Sun, and Shufang Chang, “Dual-mode imaging and therapeutic effects of drug-loaded phase-transition nanoparticles combined with near-infrared laser and low-intensity ultrasound on ovarian cancer,” Drug Delivery, vol. 25, no. 1, pp. 1683–1693, 2018. View at Publisher · View at Google Scholar
  • Chelsea Pinkham, Aslaa Ahmed, Nicole Bracci, Aarthi Narayanan, and Kylene Kehn-Hall, “Host-based processes as therapeutic targets for Rift Valley fever virus,” Antiviral Research, 2018. View at Publisher · View at Google Scholar
  • Colin Marshall, Maharshi A. Rajdev, Bhanusupriya Somarouthu, Nikhil H. Ramaiya, and Francesco Alessandrino, “Overview of systemic treatment in recurrent and advanced cervical cancer: a primer for radiologists,” Abdominal Radiology, 2018. View at Publisher · View at Google Scholar
  • Gerald Falchook, Robert L. Coleman, Andrzej Roszak, Kian Behbakht, Ursula Matulonis, Isabelle Ray-Coquard, Piotr Sawrycki, Linda R. Duska, William Tew, Sharad Ghamande, Anne Lesoin, Peter E. Schwartz, Joseph Buscema, Michel Fabbro, Alain Lortholary, Barbara Goff, Razelle Kurzrock, Lainie P. Martin, Heidi J. Gray, Siqing Fu, Emily Sheldon-Waniga, Huamao Mark Lin, Karthik Venkatakrishnan, Xiaofei Zhou, E. Jane Leonard, and Russell J. Schilder, “Alisertib in Combination With Weekly Paclitaxel in Patients With Advanced Breast Cancer or Recurrent Ovarian Cancer,” JAMA Oncology, pp. e183773, 2018. View at Publisher · View at Google Scholar
  • Leyla Norouzi-Barough, Mohammad Reza Sarookhani, Mohammadreza Sharifi, Sahar Moghbelinejad, Saranaz Jangjoo, and Rasoul Salehi, “Molecular mechanisms of drug resistance in ovarian cancer,” Journal of Cellular Physiology, 2018. View at Publisher · View at Google Scholar
  • Xue Wang, Jin Niu, Jun Li, Xiaomeng Shen, Shichen Shen, Robert M. Straubinger, and Jun Qu, “ Temporal Effects of Combined Birinapant and Paclitaxel on Pancreatic Cancer Cells Investigated via Large-Scale, Ion-Current-Based Quantitative Proteomics (IonStar) ,” Molecular & Cellular Proteomics, vol. 17, no. 4, pp. 655–671, 2018. View at Publisher · View at Google Scholar
  • Lingfeng He, Huan Yang, Shiying Zhou, Hong Zhu, Huiwen Mao, Zhuang Ma, Ting Wu, Alagamuthu Karthick Kumar, Chandrasekhar Kathera, Avilala Janardhan, Feiyan Pan, Zhigang Hu, Yanhua Yang, Libo Luo, and Zhigang Guo, “Synergistic antitumor effect of combined paclitaxel with FEN1 inhibitor in cervical cancer cells,” DNA Repair, 2018. View at Publisher · View at Google Scholar
  • Hossein Sadeghi, Najmeh Rahmanian, Fereshteh Talebpour Amiri, Hossein Amirfakhrian, Seyed Mohammad Abedi, and Seyed Jalal Hosseinimehr, “99mTc-glucarate for assessment of paclitaxel therapy in human ovarian cancer in mice,” Iranian Journal of Basic Medical Sciences, vol. 21, no. 1, pp. 77–82, 2018. View at Publisher · View at Google Scholar
  • Aya S. Khairallah, Alexandra Leary, Catherine Genestie, and Aurélie Auguste, “Impact of neoadjuvant chemotherapy on the immune microenvironment in advanced epithelial ovarian cancer: Prognostic and therapeutic implications,” International Journal of Cancer, 2018. View at Publisher · View at Google Scholar
  • Ye, Wan, Liang, Li, Liu, and Hui, “USF1 gene polymorphisms may associate with the efficacy and safety of chemotherapy based on paclitaxel and prognosis in the treatment of ovarian cancer,” Neoplasma, vol. 65, no. 1, pp. 153–160, 2018. View at Publisher · View at Google Scholar
  • Ezgi Guler, Daniel A. Smith, Bhanusupriya Somarouthu, Rahul Gujrathi, Nikhil H. Ramaiya, and Sree Harsha Tirumani, “Overview of imaging findings associated with systemic therapies in advanced epithelial ovarian cancer,” Abdominal Radiology, 2019. View at Publisher · View at Google Scholar
  • Zehra Tavsan, and Hülya Ayar Kayali, “Flavonoids showed anticancer effects on the ovarian cancer cells: Involvement of reactive oxygen species, apoptosis, cell cycle and invasion,” Biomedicine & Pharmacotherapy, vol. 116, pp. 109004, 2019. View at Publisher · View at Google Scholar
  • Amanda L. Shepherd-Littlejohn, Wyatt J. Hanft, Vanessa A. Kennedy, and Edwin A. Alvarez, “Afatinib use in recurrent epithelial ovarian carcinoma,” Gynecologic Oncology Reports, 2019. View at Publisher · View at Google Scholar
  • Farah Ballout, Zeina Habli, Alissar Monzer, Omar Nasser Rahal, Maamoun Fatfat, and Hala Gali-Muhtasib, “Anticancer Alkaloids: Molecular Mechanisms and Clinical Manifestations,” Bioactive Natural Products for the Management of Cancer: from Bench to Bedside, pp. 1–35, 2019. View at Publisher · View at Google Scholar
  • Monika Raab, Nene F. Kobayashi, Sven Becker, Elisabeth Kurunci‐Csacsko, Andrea Krämer, Klaus Strebhardt, and Mourad Sanhaji, “ Boosting the apoptotic response of high‐grade serous ovarian cancers with CCNE1 amplification to paclitaxel in vitro by targeting APC/C and the pro‐survival protein MCL‐1 ,” International Journal of Cancer, 2019. View at Publisher · View at Google Scholar
  • Buddhadev Layek, Drishti Sehgal, Peter A. Argenta, Jayanth Panyam, and Swayam Prabha, “Nanoengineering of Mesenchymal Stem Cells via Surface Modification for Efficient Cancer Therapy,” Advanced Therapeutics, pp. 1900043, 2019. View at Publisher · View at Google Scholar
  • Marco Tagliamento, Carlo Genova, Giovanni Rossi, Simona Coco, Erika Rijavec, Maria Giovanna Dal Bello, Simona Boccardo, Francesco Grossi, and Angela Alama, “Microtubule-targeting agents in the treatment of non-small cell lung cancer: insights on new combination strategies and investigational compounds,” Expert Opinion on Investigational Drugs, pp. 1–11, 2019. View at Publisher · View at Google Scholar
  • Ki-Hyun Bang, Young-Guk Na, Hyun Wook Huh, Sung-Joo Hwang, Min-Soo Kim, Minki Kim, Hong-Ki Lee, and Cheong-Weon Cho, “The Delivery Strategy of Paclitaxel Nanostructured Lipid Carrier Coated with Platelet Membrane,” Cancers, vol. 11, no. 6, pp. 807, 2019. View at Publisher · View at Google Scholar
  • Md Abul Barkat, Sarwar Beg, Faheem H Pottoo, and Farhan J Ahmad, “Nanopaclitaxel therapy: an evidence based review on the battle for next-generation formulation challenges,” Nanomedicine, vol. 14, no. 10, pp. 1323–1341, 2019. View at Publisher · View at Google Scholar
  • Michelle A. Glasgow, Peter Argenta, Juan E. Abrahante, Mihir Shetty, Shobhana Talukdar, Paula A. Croonquist, Mahmoud A. Khalifa, and Timothy K. Starr, “Biological Insights into Chemotherapy Resistance in Ovarian Cancer,” International Journal of Molecular Sciences, vol. 20, no. 9, pp. 2131, 2019. View at Publisher · View at Google Scholar
  • Xianping Dai, Feng Geng, Mengshun Li, and Ming Liu, “Tripartite motif‑containing 11 regulates the proliferation and apoptosis of breast cancer cells,” Oncology Reports, vol. 41, no. 4, pp. 2567–2574, 2019. View at Publisher · View at Google Scholar
  • Emine Cinici, Nilay Dilekmen, Zerrin Kutlu, Busra Dincer, Ozkan Cinici, Hilal Balta, and Ilknur Calık, “Carvone protects against paclitaxel-induced retinal and optic nerve cytotoxicity: a histopathological study,” Cutaneous and Ocular Toxicology, pp. 1–4, 2019. View at Publisher · View at Google Scholar
  • Moses Bio, Kazi Md Mahabubur, Irene Lim, Pallavi Rajaputra, Robert E. Hurst, and Youngjae You, “Singlet oxygen-activatable Paclitaxel prodrugs via intermolecular activation for combined PDT and chemotherapy,” Bioorganic & Medicinal Chemistry Letters, 2019. View at Publisher · View at Google Scholar
  • Xi Guo, Hong Sun, Jihong Dong, Yi Feng, Hong Li, Rongyuan Zhuang, Peipei Wang, Weimin Cai, and Yuhong Zhou, “Does nab-paclitaxel have a higher incidence of peripheral neuropathy than solvent-based paclitaxel? Evidence from a systematic review and meta-analysis,” Critical Reviews in Oncology/Hematology, 2019. View at Publisher · View at Google Scholar
  • Shuya Han, Pankaj Dwivedi, Farhana Akbar Mangrio, Monika Dwivedi, Renuka Khatik, David E. Cohn, Ting Si, and Ronald X. Xu, “Sustained release paclitaxel-loaded core-shell-structured solid lipid microparticles for intraperitoneal chemotherapy of ovarian cancer,” Artificial Cells, Nanomedicine, and Biotechnology, vol. 47, no. 1, pp. 957–967, 2019. View at Publisher · View at Google Scholar
  • Hong Sun, Xi Guo, Ziteng Wang, Peipei Wang, Zhe Zhang, Jihong Dong, Rongyuan Zhuang, Yuhong Zhou, Guo Ma, and Weimin Cai, “Alphalipoic Acid Prevents Oxidative Stress and Peripheral Neuropathy in Nab-Paclitaxel-Treated Rats through the Nrf2 Signalling Pathway,” Oxidative Medicine and Cellular Longevity, vol. 2019, pp. 1–11, 2019. View at Publisher · View at Google Scholar
  • Apriliana Cahya Khayrani, Hafizah Mahmud, Aung Ko Ko Oo, Maram H. Zahra, Miharu Oze, Juan Du, Md Jahangir Alam, Said M. Afify, Hagar A. Abu Quora, Tsukasa Shigehiro, Anna Sanchez Calle, Nobuhiro Okada, Akimasa Seno, Koki Fujita, Hiroki Hamada, Yuhki Seno, Tadakatsu Mandai, and Masaharu Seno, “Targeting Ovarian Cancer Cells Overexpressing CD44 with Immunoliposomes Encapsulating Glycosylated Paclitaxel,” International Journal of Molecular Sciences, vol. 20, no. 5, pp. 1042, 2019. View at Publisher · View at Google Scholar
  • Wan-Rong Bao, Zhi-Peng Li, Quan-Wei Zhang, Li-Feng Li, Hong-Bing Liu, Dik-Lung Ma, Chung-Hang Leung, Ai-Ping Lu, Zhao-Xiang Bian, and Quan-Bin Han, “Astragalus Polysaccharide RAP Selectively Attenuates Paclitaxel-Induced Cytotoxicity Toward RAW 264.7 Cells by Reversing Cell Cycle Arrest and Apoptosis,” Frontiers in Pharmacology, vol. 9, 2019. View at Publisher · View at Google Scholar
  • Hoon Hyun, Min Park, Gayoung Jo, So Kim, Heung Chun, and Dae Yang, “Photo-Cured Glycol Chitosan Hydrogel for Ovarian Cancer Drug Delivery,” Marine Drugs, vol. 17, no. 1, pp. 41, 2019. View at Publisher · View at Google Scholar
  • Koji Nakamura, Kae Hashimoto, Tadashi Kimura, Yasuto Kinose, Aasa Shimizu, Erika Nakatsuka, Seiji Mabuchi, Kenjiro Sawada, Mayuko Miyamoto, Akihiko Yoshimura, Kyoso Ishida, and Masaki Kobayashi, “Downregulation of miR-194-5p induces paclitaxel resistance in ovarian cancer cells by altering MDM2 expression,” Oncotarget, vol. 10, no. 6, pp. 673–683, 2019. View at Publisher · View at Google Scholar
  • Tahia K. Mohamed, Rasha Z. Batran, Samia A. Elseginy, Mamdouh M. Ali, and Abeer E. Mahmoud, “Synthesis, anticancer effect and molecular modeling of new thiazolopyrazolyl coumarin derivatives targeting VEGFR-2 kinase and inducing cell cycle arrest and apoptosis,” Bioorganic Chemistry, 2019. View at Publisher · View at Google Scholar
  • Indrayathi, I.N.G Budiana, Rasmaya Niruri, N.M. Dhatu Dewi Adnyani, Rini Noviyani, and Tunas, “Effect of paclitaxel-cisplatin chemotherapy towards hemoglobin, platelet, and leukocyte levels in epithelial ovarian cancer patients,” Journal of Applied Pharmaceutical Science, vol. 9, no. 1, pp. 104–107, 2019. View at Publisher · View at Google Scholar
  • Xiaodong Ma, Ezgi Özliseli, Yuezhou Zhang, Guoqing Pan, Dongqing Wang, and Hongbo Zhang, “Fabrication of redox-responsive doxorubicin and paclitaxel prodrug nanoparticles with microfluidics for selective cancer therapy,” Biomaterials Science, 2019. View at Publisher · View at Google Scholar
  • Mengjiao Wang, Mingji Jin, Qiming Wang, Zhonggao Gao, Zhehu Jin, Liqing Chen, and Wei Huang, “Improving the anti-keloid outcomes through liposomes loading paclitaxel–cholesterol complexes,” International Journal of Nanomedicine, vol. 14, pp. 1385–1400, 2019. View at Publisher · View at Google Scholar